Congress:
ECR25
Poster Number:
C-11988
Type:
Poster: EPOS Radiologist (scientific)
Authorblock:
R. Niemantsverdriet1, F. Hartmann1, M. P. A. Starmans1, M. Ronot2, R. L. Miclea3, V. Vilgrain2, M. Thomeer1, S. Klein1, LAI Consortium1; 1Rotterdam/NL, 2Paris/FR, 3Maastricht/NL
Disclosures:
Ruben Niemantsverdriet:
Nothing to disclose
Frederik Hartmann:
Nothing to disclose
Martijn Pieter Anton Starmans:
Nothing to disclose
Maxime Ronot:
Nothing to disclose
Razvan Lucian Miclea:
Nothing to disclose
Valérie Vilgrain:
Nothing to disclose
Maarten Thomeer:
Nothing to disclose
Stefan Klein:
Nothing to disclose
LAI Consortium:
Nothing to disclose
Keywords:
Liver, MR, Diagnostic procedure, Cancer
A consortium agreement describing data inclusion and data management procedures, governance mechanisms, intellectual property strategy, and publication policy has been approved by all partners. As a starting point for the LAI dataset, the dataset described by Starmans et al. [1] is used. This dataset consists of 486 patients with over 2500 scans, including 156 patients with hepatocellular carcinoma, 65 with intrahepatic cholangiocarcinoma, 139 with hepatocellular adenoma, and 126 with focal nodular hyperplasia. For each patient, at least a T2-weighted MRI scan is available, and for most patients dynamic contrast-enhanced T1-weighted scans covering pre-contrast, arterial, portal venous, and delayed or hepatobiliary phases as well.